Genetic counselling for those with a family history of breast or ovarian cancer: Current practice and ethical issues

Acta Oncologica

Volumn 38, Issue 5, 1999, Pages 559-565

  Richards, Martin P M ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; FAMILIAL DISEASE; FAMILY HISTORY; FEMALE; GENETIC COUNSELING; HUMAN; MALE; MEDICAL ETHICS; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT;

BREAST NEOPLASMS; ETHICS, MEDICAL; FAMILY HEALTH; FEMALE; GENETIC COUNSELING; HUMANS; MALE; OVARIAN NEOPLASMS; RISK ASSESSMENT;

EID: 0032865666     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418699431131     Document Type: Article

References (42)

1. 1. Morrison PJ. Genetic testing and insurance in the United Kingdom. Clin Genet 1998; 54; 375-9.
2. 2. Couch FJ, Weber BL. Breast cancer. In: Vogelstein B, Weber BL, eds. The genetic basis of human cancer. New York: McGraw Hill, 1998: 537-65.
3. 3. Haber DA, Fearon ER. The promise of cancer genetics. Lancet 1998; 351 (Suppl 11): 1-8.
4. 4. Bishop DT, Kierneney A. Family studies and the evidence for genetic susceptibility to prostrate cancer. Cancer Biol 1997; 8: 45-51.
5. 5. Easton DF, Ford D, Bishop DT. Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 1995; 56: 265-71.
6. 6. Fusion DF, Bishop DT, Ford D, Crockford GP. Breast Cancer Linkage Consortium. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 1993; 52: 678-701.
7. 7. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2 to chromosome 13q. Science 1994; 265: 2088-90.
8. 8. Whittemore AS, Gonr G, Itnyre J. Prevalence and contribution of BRCA1 imitations in breast cancer and ovarian cancer: results from three US population-based case-control studies of ovarian cancer., Am J. Hum Genet 1997; 60: 496-504.
9. 9. Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998; 352: 1337-9.
10. 10. Fitzgerald GM, MacDonald DJ, Krainer M, et al. Germline mutations in Jewish and non Jewish women with early-onset breast cancer. N Engl J Med 1996; 334; 143-9.
11. 11. First European Breast Cancer Conference. Florence statement, html(a) www.cortc.be 1998. pp. 2.
12. 12. Wilfond BS, Rothenberg EJ, Thomson EJ, et al. for the Cancer Genetic Studies Consortium, National Institute of Health. Cancer genetic susceptibility testing; ethical and policy implications for future research and clinical practice. J Law Med Ethics 1997; 25: 243-51.
13. 13. Ponder M, Green JM. BRCA1 testing: some issues in moving from research to service, Psychooncology 1996; 5: 223-32.
14. 14. American Society of Clinical Oncology. Genetic testing for cancer susceptibility. Oncology 1966; 14; 1730-6.
15. 15. Eeles RA, Murday VA. The cancer family clinic. In: Eeles RA, Ponder BJ, Easton DF, Horwich A, eds. Genetic predisposition to cancer. London: Chapman and Hall Medical, 1996: 356-71.
16. 16. Foulkes WD. BRCA1 and BRCA2 penetrating the clinical arena. Lancet 1998; 852: 1325-6.
17. 17. Hallowell N, Statham H, Murton F, et al. Talking about chance: the presentation of risk information during genetic counselling for breast and ovarian cancer. J Genet Counseling 1997; 6: 269-86.
18. 18. Boltorff. JL, Ratner PA, Johnson JL, Lovato CY, Joab SA. Communicating cancer risk information: the challenges of uncertainty. Patient Education and Counseling 1998; 33; 67-81.
19. 19. Hallowell N, Green JM, Statham H, et al. Recall of numerical risk estimates and counsellees' perceptions of the importance of risk information following genetic counselling for breast and ovarian cancer. Psychol Health and Med 1997; 2: 149-59.
20. 20. Hallowell N, Statham H, Murton F. Women's understanding of their risk of developing breast/ovarian cancer before and after their attendance at a cancer genetics clinic, J Genet Counseling 1998; 7: 345-64.
21. 21. Gallion HH, Park R. Developing intervention/prevention strategies for individuals at high risk of developing hereditary ovarian cancer. Cancer. J Natl Cancer Inst Mongr 1995; 17: 103-6.
22. 22. Beckman MW, Schnurch HG, Bodden-Heidrich R, et al. Early cancer detection programmes for women at high risk of breast and ovarian cancer: a proposal of practical guidelines. J Cancer Prevention 1996; 5: 468-75.
23. 23. Ferrini R. Screening asymptomatic women for ovarian cancer. American College of Preventive Medicine practice policy. Am J Prev Med 1997; 13: 444-6.
24. 24. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. 2. BRCA1 and BRCA2. J Am Med Assoc 1998; 277: 997-1003.
25. 25. Tobacman JK, Greene MH, Tucker MA, et al, Intra-abdominal carcionomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 1982; ii: 195-99.
26. 26. Ziegler LD, Kroll SS. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 1991; 14: 451-4.
27. 27. Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993; 71: 2751-5.
28. 28. Schrag D, Kurtz KM, Garber JE, Wecks JC. Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997; 336: 1465-71.
29. 29. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 77-84.
30. 30. Lerman C, Narod S. Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. J Am Med Assoc 1996; 275: 1885-92.
31. 31. Serova OM, Mazoyer S, Puget N, et al. Mutations in BRCA1 and BRCA2 in breast cancer families; are there more breast cancer susceptibility genes? Am J Hum Genet 1997; 60: 486-95.
32. 32. Pharoah P, Mackay J, Zimmern R. Managing women at high risk of breast cancer because of a family history. Paper presented at a Consensus Conference. London: January 1998.
33. 33. Green JM, Richards MPM, Murton F, Statham HE, Hallowell N. Family communication and genetic counseling. The case of hereditary breast and ovarian cancer. J Genet Counseling 1997; 6; 45-60.
34. 34. Richards MPM, Families, kinship and genetics. In: Marteau T, Richards MPM, eds. The troubled helix: social and psychological implications of the new human genetics. Cambridge: Cambridge University Press, 1996: 249-73.
35. 35. Hopwood P. Psychological issues in cancer genetics, current research and future priorities. Patient Education and Counseling 1997; 32: 19-31.
36. 36. Hallowell N, Murton F, Statham H, Green JM, Richards MPM. Women's need for information before attending genetic counselling for familial breast or ovarian cancer: a questionnaire, interview and observational study. Br Med J 1997; 314: 281-3.
37. 37. Audrain J, Rimer B, Cella D, et al. Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want? J Clin Oncol 1998; 16; 133-8.
38. 38. Wertz DC, Sorenson JR, Heeren TC. Clients' interpretation of risks provided in genetic counseling. Am J Hum Genet 1986; 9: 253-64.
39. 39. Hallowell N, Murton F. The value of written summaries of genetic consultations. Patient Education and Counseling 1998; 35: 27-34.
40. 40. Genetic Testing Working Group of the NHMRC National Breast Care Centres. Current best advice about familial aspects of breast cancer. Kings Cross: Australia, 1997.
41. 41. Report of consensus meeting on the management of women with a family history of breast cancer. Unit tor Public Health Genetics, Cambridge, UK: 1998.
42. 42. Nuffield Council on Bioethics, Mental disorders and genetics: the ethical context. London: Nuffield Council on Bioethics, 1998.